Trial Profile

An Open Label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Patients With Various Advanced or Metastatic Non-hematologic Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ifebemtinib (Primary)
Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

11 Feb 2019 Results published in the Targeted Oncology
11 Feb 2019 Results of two open-label, crossover substudies published in the Targeted Oncology
08 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com